Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies

CD19 chimeric antigen receptor (CAR) engineered NK cells have been used for treating patients with relapsed and/or refractory B cell malignancies and show encouraging outcomes and safety profile. However, the poor persistence of NK cells remains a major challenge for CAR NK cell therapy. Memory-like...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Bailin, Mai, Qiusui, Pang, Yunyi, Deng, Shikai, He, Yi, Xue, Rongtao, Xu, Na, Zhou, Hongsheng, Liu, Xiaoli, Xuan, Li, Li, Chengyao, Liu, Qifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191231/
https://www.ncbi.nlm.nih.gov/pubmed/37207215
http://dx.doi.org/10.3389/fimmu.2023.1130442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191231/
https://www.ncbi.nlm.nih.gov/pubmed/37207215
http://dx.doi.org/10.3389/fimmu.2023.1130442

Ejemplares similares